Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma [tumor_genex_44k]

ABSTRACT: Single-color gene expression profiles from 649 neuroblastoma tumors were generated using 44K oligonucleotide microarrays. We aimed at determining the association of class I HOX gene expression patterns with prognostic markers in neuroblastoma.We investigated the functional consequences of HOXC9 re-expression on neuroblastoma growth and programmed cell death. One-color gene expression analysis. Single-color gene expression profiles from 649 neuroblastoma tumors were generated using 44K oligonucleotide microarrays. Stages were classified according to the International Neuroblastoma Staging System. The expression patterns of the 39 class I HOX genes were analyzed in 649 neuroblastoma samples by microarrays, and the association with prognostic markers was determined.

ORGANISM(S): Homo sapiens

SUBMITTER: Thomas Wolf

PROVIDER: E-GEOD-45547 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Shared Molecules

Only show the datasets with similarity scores above: 0.5

Threshold

0.5

Similar Datasets

Project description:We generated gene expression profiles from 498 primary neuroblastomas using RNA-Seq and microarrays. We sought to systematically evaluate the capability of RNA deep-sequencing (RNA-Seq)-based classification for clinical endpoint prediction in comparison to microarray-based ones. The neuroblastoma cohort was randomly divided into training and validation sets, and 360 predictive models on six clinical endpoints were generated and evaluated. While prediction performances did not differ considerably between the two technical platforms, the RNA-Seq data processing pipelines, or feature levels (i.e., gene, transcript, and exon junction levels), RNA-Seq models based on the AceView database performed best on most endpoints. Collectively, our study reveals an unprecedented complexity of the neuroblastoma transcriptome, and provides guidelines for the development of gene expression-based predictive classifiers using high-throughput technologies. Sample clinical characteristics definitions: dataset: Expression data set used for classification training (1) or validation (2) Sex: M = male; F= female age at diagnosis: the age in days at diagnosis mycn status: Amplification status of the MYCN proto-oncogene (amplified = 1, no amplification = 0; no information = N/A) high risk: Clinically considered as high-risk neuroblastoma (yes=1, no= 0) INSS stage: disease stage according to International Neuroblastoma Staging System (INSS) (1, 2, 3, 4 and 4S) class label: Maximally divergent disease courses - unfavorable (= 1): patient died despite intensive chemotherapy, favorable (=0): patient survived without chemotharapy for at least 1000 days post diagnosis; not applicable (N/A) progression: Occurrence of a tumor progression event (yes=1; no=0) death from disease: Occurrence of death from the disease (yes=1; no=0) Gene expression of 498 neuroblastoma samples was quantified by RNA sequencing as well as by microarray analyses in order to understand the neuroblastoma transcriptome and predict clinical endpoints.